These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19783381)

  • 1. Introduction to College on Problems of Drug Dependence special conference on risk management and post-marketing surveillance of CNS drugs.
    Schuster CR; Barthwell AG; Henningfield JE
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S4-8. PubMed ID: 19783381
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk management and post-marketing surveillance of CNS drugs: an introduction.
    Balster RL; Johanson CE; Walsh SL
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S1-3. PubMed ID: 19744805
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk management and post-marketing surveillance of CNS drugs.
    Henningfield JE; Schuster CR
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring risk: post marketing surveillance and signal detection.
    Dart RC
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S26-32. PubMed ID: 19748743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context.
    Leiderman DB
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report.
    Johanson CE; Balster RL; Henningfield JE; Schuster CR; Anthony JC; Barthwell AG; Coleman JJ; Dart RC; Gorodetzky CW; O'Keeffe C; Sellers EM; Vocci F; Walsh SL
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1(Suppl 1):S65-71. PubMed ID: 19783383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
    Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correspondents in post- marketing surveillance, drug dependence surveillance, and toxicovigilance: definition and roles].
    Rioufol C; Vial T; Pulce C; Descotes J
    Therapie; 2002; 57(2):201-4. PubMed ID: 12185974
    [No Abstract]   [Full Text] [Related]  

  • 9. Resting assured: risk management in the prescription of controlled substances.
    Longo LP
    WMJ; 1999; 98(1):23-9. PubMed ID: 10050150
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk identification, risk assessment, and risk management of abusable drug formulations.
    Wright C; Kramer ED; Zalman MA; Smith MY; Haddox JD
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S68-76. PubMed ID: 16581201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case histories in pharmaceutical risk management.
    McCormick CG; Henningfield JE; Haddox JD; Varughese S; Lindholm A; Rosen S; Wissel J; Waxman D; Carter LP; Seeger V; Johnson RE
    Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S42-55. PubMed ID: 19767156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 13. [Post-marketing surveillance systems for psychoactive prescription drug abuse].
    Nordmann S; Frauger E; Pauly V; Rouby F; Mallaret M; Micallef J; Thirion X
    Therapie; 2011; 66(3):263-72. PubMed ID: 21819810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harm reduction is a good label for a criterion all drug programs should meet.
    Maccoun RJ
    Addiction; 2009 Mar; 104(3):341-2; discussion 345-6. PubMed ID: 19207338
    [No Abstract]   [Full Text] [Related]  

  • 15. Dutch policy on the management of drug-related problems: an Anglo-Dutch debate.
    Br J Addict; 1989 Sep; 84(9):989-97. PubMed ID: 2790278
    [No Abstract]   [Full Text] [Related]  

  • 16. WHO expert committee on drug dependence.
    World Health Organ Tech Rep Ser; 1995; 856():1-17. PubMed ID: 8928523
    [No Abstract]   [Full Text] [Related]  

  • 17. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harm reduction and the global drug control regime: contemporary problems and future prospects.
    Bewley-Taylor DR
    Drug Alcohol Rev; 2004 Dec; 23(4):483-9. PubMed ID: 15763753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conference on abuse liability assessment of CNS drugs.
    Schuster CR; Henningfield J
    Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S1-4. PubMed ID: 12759193
    [No Abstract]   [Full Text] [Related]  

  • 20. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.